December 13, 2024
CHMP recommends approval of OFEV® in children and adolescents for the treatment of a range of interstitial lung diseases
December 06, 2024
Updated data from Beamion LUNG-1 study on zongertinib shows encouraging efficacy in previously treated HER2 mutated lung cancer patients
November 05, 2024
Boehringer advances oncology research
September 30, 2024
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
July 30, 2024
Boehringer Ingelheim invests in precision cancer treatments
July 17, 2024
Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative
June 03, 2024
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
May 16, 2024
Boehringer Ingelheim unveils its first global sustainability publication ‘Imagine’
January 04, 2024
FDA grants breakthrough status to schizophrenia treatment
December 11, 2023
EU approves Jardiance® for treatment of type 2 diabetes in children aged 10 years and above
December 07, 2023
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
November 15, 2023